Check out our latest news and articles.

Visit our Blog

BaseCase Usability - Interview with Dr. Waka Udezi

BaseCase loves feedback. As we develop, the comments, recommendations and suggestions we get from users are invaluable. We gain a deeper insight into the usability and overall functionality of our platform and thus, are able to make changes that directly benefit our users. Last month, we were very grateful to receive extensive feedback from Dr. Anthony Waka Udezi, Senior Lecturer in the Department of Clinical Pharmacy at the University of Benin, one of the leading and most innovative pharmacy schools in Nigeria. Dr. Waka Udezi is currently trying to develop a model that will help determine accessibility to medicines for poor patient groups, which will eventually help decision- makers prioritize and select which medicines should be subsidized.

Dr. Anthony Waka Udezi, Senior Lecturer in the Department of Clinical Pharmacy at the University of Benin

What are the major issues/challenges in your work?

Constructing tools/models that aid in healthcare decision-making makes my work unique since such science remains unexplored in Nigeria. For example, in the presence of fake drugs should hospitals promote generic or branded drug products? What drugs need some form of subsidy to improve access? How can empirical or clinical malaria diagnosis be improved? Should a firm vaccinate its workers against typhoid fever or simply treat them when they are sick? These are just a few of the many challenges that my work provides.

What sales/visualization/technology challenges were you experiencing?

Long man hours on the computer trying to figure out the best way to present a model reduce my productivity. Poor visual displays and difficulty in explaining the underlining principles of my models was a real pain in the neck.

What challenges do you face when presenting to an external audience?

Other healthcare practitioners, who saw the complicated formulae that my models use and the arrays of numbers that are needed to aid the decision process, were easily turned off. The doctors and decision-makers that I have to talk to simply do not have the time or the patience to wade through a sea of numbers before they can reach a decision. They prefer to see a picture of where they are now and where they could end up if they implement a particular decision.

What model were you trying to visualize on BaseCase?

A drug affordability calculator which will hopefully become a full-fledged model that can be used by researchers all over the world to evaluate access to medicines by the poor, especially those who live below the poverty line.

What is the value message of your model?

The lowest paid unskilled worker, sometimes needs to work for days before they can afford simple treatments, even for minor ailments. The more a worker needs to work before they can afford a drug needed for their treatment, the less accessible the drug. This tool serves as an aid to the decision-maker to decide which drugs should be subsidized as a matter of priority.

What specific feature did you like most about BaseCase?

The ease of creating dynamic text results was particularly fascinating for me. I do not need to know any complex computer codes!

What are top three benefits of using BaseCase?

  • Very easy to learn hence you become productive almost immediately.
  • Ease of use. You do not need to type numbers all the time to use the models: just move the sliders!
  • Superb visuals that communicate results in a way that is easy to understand.

Would you recommend BaseCase?

Yes, I would strongly recommend BaseCase. It has a rapid learning curve and a BaseCase user can become productive within a few hours of use. The superb visualization features communicate results effectively without intimidating the end user with a sea of numbers.

As Dr. Waka Udezi’s work aims to benefit the poor by helping decision-makers make more informed and rapid decisions about medical treatments, we sincerely hope that BaseCase can facilitate that development and increase the access to affordable medicine.